Rhone Poulenc has declared impressive results with a 30.3% growth in net profit on the back of a 18% rise in the sales. The operating margins have increased by 90 basis points in the current quarter vis–a–vis the corresponding quarter of the last year. Rhone is the second biggest player in the Rs 4.84 bn cough and colds segment after Pfizer. It's product Phensedyl ranks only next to Pfizer's Corex in terms of market share. The product which grew by 21% last year, contributes more than 15% to the company's turnover.
(Rs m) | 3QFY00 | 3QFY01 | Change |
Sales | 517 | 610 | 18.0% |
Other Income | 21 | 33 | 53.7% |
Expenditure | 432 | 505 | 16.8% |
Operating Profit (EBDIT) | 85 | 106 | 24.1% |
Operating Profit Margin (%) | 16.4% | 17.3% | |
Interest | 1 | 1 | |
Depreciation | 7 | 7 | -9.6% |
Profit before Tax | 98 | 131 | 33.5% |
Other Adjustments | - | ||
Tax | 34 | 48 | 39.7% |
Profit after Tax/(Loss) | 64 | 84 | 30.3% |
Net profit margin (%) | 12.4% | 13.7% | |
Earnings per share* | 56.98 | 74.22 | |
*annualised |
A 40% stake in the company was recently acquired by Nicholas Piramal, which has made an open offer for another 20% stake under the SEBI guidelines at a price of Rs 875.
The stock quotes at Rs 760, which implies an earnings multiple of less than 11 times 3QFY01 annualised earnings.
Sorry! There are no related views on news for this company/sector.
In this video, I'll tell you why I am recommending caution in the market at this time.
A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.
In this video I'll show you exactly how I go about picking stocks for trading.
100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.
More
Equitymaster requests your view! Post a comment on "Rhone Poulenc: Ace after the takeover". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!